MetaVia Reports Positive Top-Line Data From Phase 1 MAD Study Of DA-1726 To Treat Obesity

(RTTNews) - MetaVia Inc. (MTVA), a clinical-stage biotechnology company, Tuesday reported positive results from the 4-week multiple ascending dose (MAD) Part 2 of its Phase 1 study of DA-1726 for the treatment of obesity.

The Phase 1 study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending doses of DA-1726 in obese, otherwise healthy subjects. In the MAD portion of the study, DA-1726 showed excellent safety and tolerability, with positive clinical activity. The cohort receiving 32 mg of DA-1726 with no titration demonstrated a maximum weight loss of 6.3 percent and a mean weight loss of 4.3 percent at day 26.

With the mean baseline of 41 inches, DA-1726 showed an average reduction in waist circumference of 1.6 inches, with a maximum reduction of 3.9 inches by day 33.

The company plans to conduct a Phase 1 Part 3 study to evaluate DA-1726 on Wegovy early drop-out patients. Novo Nordisk's Wegovy is approved by the FDA for chronic weight management in adults with obesity.